Every Formula 1 Grand Prix has its strategic pit stops where advantages are gained by resets and deploying fresh tyres with astonishing precision, agility and speed. For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.
Safety and privacy are valid reasons to ease back on the throttle, but expectant patients, healthcare professionals (HCPs) and key opinion leaders (KOLs) want to see digital and technological advances powering the rapid progress they
witness daily in other sectors.
Generative AI (GenAI) is already flourishing across drug discovery, clinical
trials and healthcare system recalibration, but many fear its potential power is dissipating through lack of co-ordinated application across departments.
For launch excellence, where the cost of developing a drug has risen to $2.2bn in 2024 from $2.1bn the previous year, this is the equivalent of skidding out of a corner and watching the rev counter dwindle.
AI’s impact is accepted and its potential is revered, but industry is being
challenged to move through the gears so that every aspect of business benefits, rather than admiring pilot schemes that are tested in isolation.
Read the article in full here.